Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug …
…, L Fox, D Stresser, C Butters, P Sharma, DD Surry - Xenobiotica, 2011 - Taylor & Francis
Full article: Validation of membrane vesicle-based breast cancer resistance protein and
multidrug resistance protein 2 assays to assess drug transport and the potential for drug–drug …
multidrug resistance protein 2 assays to assess drug transport and the potential for drug–drug …
The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672
…, G Imisson, P Sharma, V Smith, DD Surry - Drug metabolism and …, 2011 - ASPET
To support drug development and registration, Caco-2 cell monolayer assays have
previously been set up and validated to determine whether candidate drugs are substrates or …
previously been set up and validated to determine whether candidate drugs are substrates or …
Antagonists of the Human A2A Adenosine Receptor. 4. Design, Synthesis, and Preclinical Evaluation of 7-Aryltriazolo[4,5-d]pyrimidines
…, DL Selwood, GC Stratton, D Surry… - Journal of medicinal …, 2009 - ACS Publications
Antagonism of the human A 2A receptor has been implicated as a point of therapeutic intervention
in the alleviation of the symptoms associated with Parkinson’s disease. This is thought …
in the alleviation of the symptoms associated with Parkinson’s disease. This is thought …
Solitary inhibition of the breast cancer resistance protein efflux transporter results in a clinically significant drug-drug interaction with rosuvastatin by causing up to a 2 …
R Elsby, P Martin, D Surry, P Sharma… - Drug Metabolism and …, 2016 - ASPET
The intestinal efflux transporter breast cancer resistance protein (BCRP) restricts the absorption
of rosuvastatin. Of the transporters important to rosuvastatin disposition, fostamatinib …
of rosuvastatin. Of the transporters important to rosuvastatin disposition, fostamatinib …
Prediction of the in vivo OATP1B1-mediated drug–drug interaction potential of an investigational drug against a range of statins
…, CJ Butters, V Smith, R Elsby, D Surry - European journal of …, 2012 - Elsevier
To support drug development, the drug–drug interaction potential (DDI) of an investigational
drug (AZX) was assessed against the probe estradiol 17β-glucuronide as well as against …
drug (AZX) was assessed against the probe estradiol 17β-glucuronide as well as against …
Gene expression profiling of drug metabolism and toxicology markers using a low-density DNA microarray
F De Longueville, D Surry, G Meneses-Lorente… - Biochemical …, 2002 - Elsevier
DNA microarrays are useful tools to study changes of gene expression in response to a
treatment with drugs. Here, we describe the optimization of conditions for the cDNA synthesis …
treatment with drugs. Here, we describe the optimization of conditions for the cDNA synthesis …
The use of bioreactors as in vitro models in pharmaceutical research
M Ginai, R Elsby, CJ Hewitt, D Surry, K Fenner… - Drug Discovery …, 2013 - Elsevier
Bringing a new drug to market is costly in terms of capital and time investments, and any
development issues encountered during late-stage clinical trials can often be the result of in vitro…
development issues encountered during late-stage clinical trials can often be the result of in vitro…
Comparison of the effects of some CYP3A and other enzyme inducers on replicative DNA synthesis and cytochrome P450 isoforms in rat liver
…, AB Renwick, ME Cunninghame, RJ Price, D Surry… - Toxicology, 1998 - Elsevier
The aim of this study was to investigate the mitogenic effects of some inducers of cytochrome
P450 (CYP) isoforms in rat liver. Female Sprague-Dawley CD rats were treated with 100 mg…
P450 (CYP) isoforms in rat liver. Female Sprague-Dawley CD rats were treated with 100 mg…
Quantification of proteins by flow cytometry: Quantification of human hepatic transporter P-gp and OATP1B1 using flow cytometry and mass spectrometry
…, R Coldwell, DJ Weston, J Pillmoor, D Surry… - Methods, 2015 - Elsevier
… (D) An example of QIFIKIT® calculations using 5 calibration bead populations, the observed
MFI and … 1D). This is an important control to ensure that the cytometer, beads and antibodies …
MFI and … 1D). This is an important control to ensure that the cytometer, beads and antibodies …
In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug–drug interaction with methotrexate
…, C Butters, P Sharma, V Smith, D Surry - European journal of …, 2011 - Elsevier
Methotrexate is the most commonly used drug to treat rheumatoid arthritis. Since clinical
efficacy studies in rheumatoid arthritis are conducted on a background of methotrexate therapy, …
efficacy studies in rheumatoid arthritis are conducted on a background of methotrexate therapy, …